Evidence map›Paper›PMID 40921866›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025

Incidence, risk factors, prognosis of periprosthetic fractures post hip fracture: unveiling protective role of anti-osteoporotic medication.

Shao-Wei Lo, Hung-Kuan Yen, Chi-Ching Huang, Yi-Chien Lu, Ho-Min Chen, Jou-Wei Lin, Shau-Huai Fu, Chen-Yu Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shao-Wei Lo *Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Hung-Kuan Yen *Department of Orthopaedic Surgery, National Taiwan University Hospital, Taipei, Taiwan.
Chi-Ching HuangDepartment of Emergency Medicine, Lehigh Valley Health Network, Allentown, PA, USA.
Yi-Chien LuNational Center for Geriatrics and Welfare Research, National Health Research Institutes, Yunlin County, Taiwan.
Ho-Min ChenHealth Data Research Center, National Taiwan University, Taipei, Taiwan.
Jou-Wei LinCardiovascular Center, National Taiwan University Hospital Yun Lin Branch, Douliu, Yunlin, Taiwan.
Shau-Huai Fu *Department of Orthopaedic Surgery, National Taiwan University Hospital, Taipei, Taiwan. b90401045@gmail.com.
Chen-Yu Wang *National Center for Geriatrics and Welfare Research, National Health Research Institutes, Yunlin County, Taiwan. valinawang0220@gmail.com.ORCID http://orcid.org/0000-0003-0498-2438

Funding

National Science and Technology Council NSTC 111-2314-B-002-103-MY2National Science and Technology Council NSTC 113-2314-B-400-005National Taiwan University Hospital Yunlin Branch NTUHYL110.AOO3National Taiwan University Hospital Yunlin Branch NTUHYL112-X021
6 · The paper itself

Abstract

People with a hip fracture are prone to break the bone around the metal repair, causing severe health issues. This study found that initiating anti-osteoporotic medication soon after the first fracture halves that risk, highlighting the benefit of early osteoporosis treatment.

backgroundHip fractures pose significant clinical challenges, often leading to prolonged hospitalization, reduced quality of life, and increased risk of subsequent fractures. Periprosthetic fractures (PPFs), which occur near hip fixation devices, are particularly concerning due to their high morbidity and mortality. This study evaluates the incidence, risk factors, and outcomes of PPFs and examines whether initiating anti-osteoporotic medication (AOM) after hip fracture reduces PPF risk.

methodsWe conducted a retrospective cohort study using Taiwan's National Health Insurance Research Database, analyzing 48,082 patients with hip fractures from January 2016 to December 2018. We assessed the incidence, risk factors, and prognosis of PPFs, including mortality and subsequent major osteoporotic fractures (SMOFs), and compared these outcomes to those with contralateral second hip fractures (2HFs). The effect of AOM initiation post-hip fracture was also evaluated.

resultsAmong the cohort, 443 patients (0.9%) developed PPFs, and 2285 (4.8%) experienced 2HFs. Patients aged 60-69 had a higher PPF risk. AOM use was significantly associated with reduced risk of both PPFs (HR 0.50; 95% CI, 0.39-0.65) and 2HFs (HR 0.85; 95% CI, 0.77-0.93). Five-year mortality was comparable between PPF and 2HF groups (33.0% vs. 30.0%), but SMOFs were more frequent in PPF cases (7.5% vs. 3.7%).

conclusionsPPFs are a serious complication following hip fracture. Post-fracture AOM initiation appears to lower the risk of PPFs and 2HFs, supporting its role as a key preventive strategy. Further research is needed to optimize treatment protocols.

Indexed as

Bone Density Conservation AgentsHip FracturesOsteoporotic FracturesPeriprosthetic FracturesAgedAged, 80 and overArthroplasty, Replacement, HipDatabases, FactualFemaleHumansIncidenceMaleMiddle AgedOsteoporosisPrognosisRetrospective StudiesBone Density Conservation AgentsHip fracturesOsteoporotic treatmentsPeriprosthetic fracturesPrevention

Identifiers

PMID40921866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.